Lupus Nephritis Market Report 2025

The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to factors such as increased research investments in lupus nephritis, a rising incidence of autoimmune diseases, higher healthcare spending, the growing adoption of biologics, and the increasing popularity of telemedicine.

The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the rising awareness among physicians, greater adoption of biologic therapies, an increasing number of specialty clinics, a growing emphasis on renal transplantation, and improved access to nephrology services. Key trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, the discovery of novel diagnostic biomarkers, an expansion of clinical trials, and progress in stem cell therapy.

The increasing prevalence of genetic predisposition is expected to drive the growth of the lupus nephritis market in the future. Genetic predisposition refers to inherited genetic traits that make an individual more likely to develop certain diseases or conditions. Factors such as inheritance, environmental influences, and gene mutations contribute to the rising prevalence of genetic predisposition. This predisposition plays a key role in the development of lupus nephritis, highlighting the influence of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For example, in October 2024, the Cystic Fibrosis Trust reported that the UK CF Registry recorded 11,148 patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% rise in cystic fibrosis (CF) patients. Therefore, the growing prevalence of genetic predisposition is contributing to the growth of the lupus nephritis market.

Companies in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to improve treatment outcomes and long-term kidney function for patients. These inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc. received approval from the Japanese Ministry of Health, Labour, and Welfare for LUPKYNIS (voclosporin) as a treatment for lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on the positive results from the AURORA Clinical Program, which demonstrated the drug's safety and efficacy. This approval marks a significant step forward in expanding treatment options for lupus nephritis patients in Japan, improving both disease management and outcomes.

In March 2024, Lupus Therapeutics, an affiliate clinical research partner of the Lupus Research Alliance, partnered with Artiva Biotherapeutics Inc. to support a clinical trial for lupus nephritis. This collaboration aims to conduct a Phase 1 trial to evaluate Artiva's AlloNK therapy with anti-CD20 antibodies for patients with active lupus nephritis. The trial will assess the safety and effectiveness of this potential treatment for this severe kidney complication. Artiva Biotherapeutics is a biotechnology company based in the US that develops treatments for lupus nephritis.

Major players in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, and Bionxt Solutions.

Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in lupus nephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lupus nephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lupus nephritis is a severe kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system erroneously attacks healthy tissues, including the kidneys. This inflammation can result in kidney damage, reduced function, and, if left untreated, potentially lead to kidney failure. Early diagnosis and treatment are essential for managing the disease effectively.

Lupus nephritis progresses through different stages, including class 1, class 2, class 3, and others. Class 1 represents a stage with minimal kidney damage, where kidney function remains stable, and symptoms are generally not apparent. Treatment at this stage focuses on preventing further progression of the disease. Common drug classes used in treatment include immunosuppressive drugs, corticosteroids, biological agents, and antimalarial drugs, which can be administered orally, parenterally, and through other routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, and others.

The lupus nephritis market research report is one of a series of new reports that provides lupus nephritis market statistics, including lupus nephritis industry global market size, regional shares, competitors with a lupus nephritis market share, detailed lupus nephritis market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. This lupus nephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.